Clinical Trial Update: Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating definitive chemoradiation therapy combined with durvalumab and tremelimumab for inoperable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN